GHK-Cu vs Hexapeptide-9
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Copper Peptide, Glycyl-L-histidyl-L-lysine copper
GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.
Also: Collaxyl, Collaxyl IS
Hexapeptide-9 is a collagen-inspired signaling peptide sold as Collaxyl (originally from Vincience, now Ashland) for anti-wrinkle and firming skincare. The idea is that a small repeat of a collagen sequence nudges skin cells to rebuild the junction between the outer and inner skin. It is a cosmetic ingredient, and the evidence for the original peptide is mostly old, small and company-run, although a 2025 trial on a modified cyclic version is more interesting.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- GHK-Cu has stronger research evidence (Human Trials) compared to Hexapeptide-9 (Limited Research).
Detailed Comparison
| Attribute | GHK-Cu | Hexapeptide-9 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GHK has a strong affinity for copper(II) ions and forms the GHK-Cu complex, which is thought to deliver copper to cells for copper-dependent processes such as connective-tissue formation and antioxidant defense. Its most striking documented activity is broad gene-expression modulation: in cultured human cells, GHK shifts the expression of a large fraction of genes, tending to upregulate tissue-repair genes and downregulate some inflammatory pathways. It stimulates fibroblasts to produce collagen and other extracellular-matrix proteins, supports keratinocyte and blood-vessel activity, and shows antioxidant and anti-inflammatory effects in lab models. Importantly, the copper-binding hypothesis does not fully explain these gene effects, and researchers note the precise mechanism is not yet fully understood. | Hexapeptide-9 is Gly-Pro-Gln-Gly-Pro-Gln, a repeat taken from collagen sequences. Ashland says the sequence is found in collagen IV and XVII and works as a matrikine, a matrix fragment that signals cells to make more matrix proteins. The claimed targets are the dermal-epidermal junction (collagen IV, laminin-5, integrins) and collagen production. The original patent describes it as designed to improve cell adhesion and possibly support matrix production. One weakness is stability: the linear peptide is easily broken down by collagen-digesting enzymes, which is why a Chinese group built a ring-shaped (cyclized) version to make it last longer in skin. |
| Common Dosing | 1-2 mg daily systemically, or 0.05% in cosmetic formulations Once daily | Low single-digit percent of the ingredient in a finished product Once or twice daily |
| Administration | Subcutaneous injection or topical application | Topical (serums, creams) |
| Typical Duration | Varies by application | 4-8 weeks in studies; ongoing use to maintain any effect |
| Best Time to Take | Evening (for skin/recovery) | Morning and/or evening, on clean skin |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Much of the mechanistic and efficacy evidence is from cell culture and animal studies. In animals, GHK and GHK-containing dressings improved wound contraction, granulation tissue and collagen deposition in rabbit and rat wounds, and showed protective effects in lung-injury models. In cells, GHK increases collagen, elastin and growth-factor production by fibroblasts and protects keratinocytes from UV damage. Human evidence exists but is limited to small cosmetic trials: facial-cream and eye-cream studies in modest numbers of women (for example a 71-subject facial study and a 41-subject eye-cream study) reported improvements in skin density, thickness and wrinkle appearance. These trials are small and focused on topical skin endpoints, so they do not establish injected or systemic benefits, and there are no large independent randomized trials. Honest summary: strong lab and animal data plus encouraging small topical human studies, but evidence for injected use is preliminary. | The oldest human data is a 2004 study from Vincience, the lab behind Collaxyl: a double-blind, placebo-controlled test of a gel containing 3% of a 'collagen-like hexapeptide' plus a 1% booster ingredient, applied around the eyes of 20 women for four weeks. It reported fewer and shallower wrinkles on skin replicas, but the booster and the small size mean it cannot prove the peptide alone did the work. Supplier material cites other 28-day studies in about 20 volunteers that we could not trace to journals. The newest and best-designed study is a 2025 randomized, double-blind trial in the Journal of Cosmetic Dermatology (96 adults aged 30-55 in China) comparing a cyclized hexapeptide-9 serum at 0.002% with 0.002% retinol and a vehicle for 56 days. The cyclized peptide beat both on wrinkle, elasticity and hydration measures, with no treatment-related side effects. Two caveats: it tested a modified molecule, not the Collaxyl peptide in most products, and several authors are affiliated with cosmetic companies. Bottom line: the concept has some support, the cyclic version looks promising, but regular hexapeptide-9 in a store-bought cream rests on thin evidence. |
Frequently Asked Questions: GHK-Cu vs Hexapeptide-9
What is the difference between GHK-Cu and Hexapeptide-9?
GHK-Cu is a skin & hair peptide that ghk-cu is the copper(ii) complex of ghk, a naturally occurring human tripeptide (glycyl-l-histidyl-l-lysine) found in blood plasma, saliva and urine, whose levels decline with age. it is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. it is not an fda-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies. Hexapeptide-9 is a skin & hair peptide that hexapeptide-9 is a collagen-inspired signaling peptide sold as collaxyl (originally from vincience, now ashland) for anti-wrinkle and firming skincare. the idea is that a small repeat of a collagen sequence nudges skin cells to rebuild the junction between the outer and inner skin. it is a cosmetic ingredient, and the evidence for the original peptide is mostly old, small and company-run, although a 2025 trial on a modified cyclic version is more interesting. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHK-Cu or Hexapeptide-9?
Neither is universally "better" - the choice depends on your specific goals. GHK-Cu is typically used for skin & hair purposes, while Hexapeptide-9 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHK-Cu and Hexapeptide-9 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHK-Cu and Hexapeptide-9 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.